The non-structural 5A (NS5A) protein of HCV is a multifunctional phosphoprotein involved in regulation of viral replication and virion assembly. NS5A inhibitors targeting domain I of NS5A protein have demonstrated high potency and pan-genotypic antiviral activity, however they possess a low genetic barrier to resistance. At present, only genotype 1, the most prevalent HCV genotype has been studied in detail for resistant variants.
Methods
Utilizing a panel of genotypic-specific resistance assays, population sequencing was performed on plasma-derived viral RNA isolated from 138 patients infected with HCV genotypes 1–4 and not treated with direct-acting antiviral agents. Amino acid changes in HCV NS5A domain I at codon positions 28, 30, 31, 32 and 93, reported to confer reduced susceptibility to certain NS5A inhibitors were examined. Additionally, genotypic outcome based on NS5A sequences were compared with VERSANT HCV Genotype Assay (LiPA) 1.0 (Siemens Healthcare Diagnostics, Surrey, UK) and Abbott m2000 RealTime HCV genotype II assay (Abbott Molecular, Maidenhead, Berkshire, UK).
Results
Amino acid substitutions associated with moderate to high level resistance to NS5A inhibitors were detected in 2/42 (4.76%) HCV-1a, 3/23 (13.04%) HCV-1b, 4/26 (15.38%) HCV-2, 1/24 (4.17%) HCV-3 and 1/23 (4.35%) HCV-4 infected patients who had not been treated with NS5A inhibitors. Genotype prediction based on NS5A sequences were concordant with LiPA and/or Abbott Real-Time for 97.10% of cases.
Conclusions
Primary resistance mutations associated with resistance to first-generation NS5A inhibitors such as daclatasvir were observed in all genotypes, albeit at low frequencies. An excellent correlation based on NS5A genotyping and LiPA or Abbott Real-Time was achieved.
References
1.
BeldaO., Targett-AdamsP.Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein.Virus Res2012; 170: 1–14.
2.
GaoM.Antiviral activity and resistance of HCV NS5A replication complex inhibitors.Curr Opin Virol2013; 3: 1–7.
3.
FridellR.A., WangC., SunJ.H.Genotypic and phenotypic analysis of variants resistant to hepatitis C virus non-structural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.Hepatology2011; 54: 1924–1935.
4.
LawitzE.J., GruenerD., HillJ.M.A Phase 1, randomized placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.J Hepatol2012; 57: 24–31.
5.
GaoM., NettlesR., BelemaM.Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.Nature2010; 465: 96–100.
6.
FridellR.A., QiuD., WangC., ValeraL., GaoM.Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.Antimicrob Agents Chemother2010; 54: 3641–3650.
7.
LokA.S., GardinerD.F., LawitzE.Preliminary study of two antiviral agents for hepatitis C genotype 1.N Engl J Med2012; 366: 216–224.
8.
AvóA.P., Água-DoceI., AndradeA., PáduaE.Hepatitis C virus subtyping based on sequencing of the C/E1 and NS5B genomic regions in comparison to a commercially available line probe assay.J Med Virol2013; 85: 815–822.
9.
PawlotskyJ.M.NS5A inhibitors in the treatment of hepatitis C.J Hepatol2013; 59: 375–382.
10.
SunJ.H., O'BoyleD.R.II, ZhangY.Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus non-structural protein 5A replication complex inhibitor, BMS-79005.Hepatology2012; 55: 1692–1699.
11.
MayersD.L., VinceB., HillJ.M.IDX719, HCV NS5A inhibitor, demonstrates pan-genotypic activity after three days of monotherapy in genotype 1, 2, 3 or 4 HCV-infected subject.Hepatology2012; 56: 1020A.
12.
HernandezD., ZhouN., UelandJ.Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors.J Clin Virol2013; 57: 13–18.
13.
WangC., ValeraL., JiaL., KirkM.J., GaoM., FridellR.A.In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A.Antimicrob Agents Chemother2013; 57: 611–613.
14.
WangC., LinglingL., HuangH.In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.Antimicrob Agents Chemother2012; 56: 1588–1590.
15.
PlazaZ., SorianoV., VispoE.Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor.Antivir Ther2012; 17: 921–926.
16.
SuzukiF., SezakiH., AkutaN.Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.J Clin Virol2012; 54: 352–354.
17.
KarinoY., ToyotaJ., IkedaK.Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.J Hepatol2013; 58: 646–654.
18.
Max Planck Institut Informatik.geno2pheno. (Accessed 30 September 2013.) Available from www.geno2pheno.org.
